Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Didanosine

FDA-approved product (tablet, chewable, oral), marketed as Didanosine, Videx, Videx Ec.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Didanosine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF02

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Didanosine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Didanosine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Didanosine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

    NCT00158470 · start 2003-09

    Registered record
    Registry ID
    NCT00158470
    Conditions
    HIV Infection
    Interventions
    efavirenz; didanosine; lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2007-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionefavirenz; didanosine; lamivudine
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

    NCT00005018 · start 1999-07

    Registered record
    Registry ID
    NCT00005018
    Conditions
    HIV Infections
    Interventions
    Hydroxyurea; Abacavir sulfate; Efavirenz; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1999-07
    Completion
    2000-10
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionHydroxyurea; Abacavir sulfate; Efavirenz; Didanosine
    PhasePhase 4
    Registry statusCompleted

  • Combination Drug Treatment of Pediatric HIV Infection

    NCT00001818 · start 1999-06

    Registered record
    Registry ID
    NCT00001818
    Conditions
    HIV Infection
    Interventions
    Hydroxyurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1999-06
    Completion
    2001-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionHydroxyurea
    PhasePhase 1
    Registry statusCompleted

  • A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

    NCT00002411 · start 1998-03

    Registered record
    Registry ID
    NCT00002411
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1998-03
    Completion
    1999-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Lamivudine; Stavudine; Zidovudine +1 more
    PhaseNot applicable
    Registry statusCompleted

  • A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

    NCT00002176 · start 1997-05

    Registered record
    Registry ID
    NCT00002176
    Conditions
    HIV Infections
    Interventions
    Hydroxyurea; Nelfinavir mesylate; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-05
    Completion
    2000-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionHydroxyurea; Nelfinavir mesylate; Stavudine; Didanosine
    PhaseNot applicable
    Registry statusCompleted

  • A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

    NCT00000656

    Registered record
    Registry ID
    NCT00000656
    Conditions
    HIV Infections
    Interventions
    Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1993-11
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine; Didanosine
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

    NCT00000669

    Registered record
    Registry ID
    NCT00000669
    Conditions
    HIV Infections
    Interventions
    Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDidanosine
    PhasePhase 1
    Registry statusCompleted

  • A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)

    NCT00000781

    Registered record
    Registry ID
    NCT00000781
    Conditions
    HIV Infections
    Interventions
    Nevirapine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-09
    Enrolment
    1,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine; Zidovudine; Zalcitabine; Didanosine
    PhasePhase 2
    Registry statusCompleted

  • Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

    NCT00000810

    Registered record
    Registry ID
    NCT00000810
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Zidovudine; Didanosine
    PhasePhase 1
    Registry statusCompleted

  • A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

    NCT00000814

    Registered record
    Registry ID
    NCT00000814
    Conditions
    HIV Infections
    Interventions
    Nevirapine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-11
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine; Zidovudine; Didanosine
    PhasePhase 1
    Registry statusCompleted

  • Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

    NCT00000838

    Registered record
    Registry ID
    NCT00000838
    Conditions
    HIV Infections
    Interventions
    Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-03
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamivudine; Stavudine; Zidovudine; Didanosine
    PhasePhase 2
    Registry statusCompleted

  • A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

    NCT00000902

    Registered record
    Registry ID
    NCT00000902
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Nevirapine; Lamivudine; Stavudine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-04
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Nevirapine; Lamivudine +4 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

    NCT00000918

    Registered record
    Registry ID
    NCT00000918
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir; Efavirenz; Saquinavir; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir +6 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Compare Two Different Anti-HIV Drug Regimens

    NCT00000924

    Registered record
    Registry ID
    NCT00000924
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Nevirapine; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2001-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Nevirapine; Stavudine +1 more
    PhasePhase 2
    Registry statusCompleted